The highlight of our study is the discovery of frequent alterations of the tumour suppressor SETD2 gene by loss-of-function mutations and/or loss of the corresponding 3p.21 locus in the majority of the cases (14/15). This evidence concerns the gene SETD2 and neoplasm.